Our premium daily note on how the Chinese government is reining in big tech, digitizing finance, regulating data, driving innovation, and building the next-generation infrastructure to power its digital economy.
China policy for everyone! Our free daily email covering today’s hottest development in politics, policy, and the business environment.
Want more depth?
Sign up for a paid Neopol account for access to daily analysis, deep dive reports, and online events.
Your weekly insight into the debates and developments driving China’s climate policy. Produced by the Trivium Energy team. We cover government strategy, carbon trading, green finance, and emerging tech.
Analysis on the single hottest policy development of the day. In your inbox Monday-Friday.
Hire one of the world’s best China-focused analysis teams – for less than the cost of one full-time hire.
Regular reporting on Chinese government moves in your sector – and what they mean for you.
Have questions? We’ll find answers. Our researchers produce industry-leading insights to inform your China strategy.
Trivium subscriptions keep you up to date on what the Chinese government is doing, saying, and thinking. Subscribers get access to daily policy updates and analysis via email and our ouline platform.
compare subscriptionsOur teams parse hundreds of Chinese government documents each day – but bring you only the developments that matter.
Trivium takes great care to write China analysis that human beings love to read.
It sounds trite – but it’s true: Our team is uniquely obsessed with China policy.
The Trump administration is considering blocking US pharma companies from buying Chinese-developed drug candidates. Per the New York Times: “At the heart of the possible clampdown is a drafted executive order that threatens to cut off the pipeline of Chinese-invented experimental treatments.” “The prospect of the order…has set off furious behind-the-scenes lobbying efforts by two diametrically opposed groups — each
Read it